17.9 C
New York
Thursday, May 19, 2022

ENDRA Life Sciences Inc (NDRA) stock trading high during after-hours. Here’s why

ENDRA Life Sciences Inc (NDRA) stock is trading high during the after-hours after gaining 29.54% to $0.579 on the last check. NDRA stock was also up during the recent trading session by 12.5% to $0.45. The stock is soaring without any recent news. The latest press release by the firm came on 31 March 2022. NDRA got the Key Quality Management certificate. On the same day, the firm published the financial results and gave an outlook. ENDRA Life Sciences also filed forms 3, 4, and 5 with the SEC on 30 March 2022.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


What is happening with NDRA stock?

On 31 March 2022, the firm declared to have received the quality management certificate from the British Standards Institution (BSI). This certification avows the organization’s Quality Management System (QMS) meets generally current administrative necessities well defined for the clinical device sector. NDRA got ISO 13485:2016 from the BSI. The FDA has proposed taking on the ISO 13485:2016 norm, with an end goal to orchestrate the FDA Quality System Regulation, with the global norm.

NDRA also published the results for Q4 and FY2021. The firm reported an operating expense of $3.1 million during 4Q of FY2021 versus $2.3 million in 4Q of FY2020. Also, the operating expense in FY2021 was $11.4 million against $11.5 million in FY2020.

Moreover, NDRA’s total loss in the last term of FY2021 was reported to be $3.1 million as compared to $2.3 million in a similar period of FY2020. The total loss in FY2021 was $11.2 million versus $11.7 million in FY2020.

Besides, NDRA posted a loss of $0.07 and $0.28 per stock in 4Q and FY2021, respectively.

The CEO of ENDRA Life Sciences commented that they are satisfied to have progressed their working plan in 2021 and into 2022 under testing worldwide economic situations confronting a resurgence of COVID-19 during that time. He further added that they are laser-centered around inclining up their worldwide clinical exploration destinations to produce information to help commercialization.

How is the industry performing?

The biotech sector has performed inadequately in the previous year. The experts are proposing numerous explanations behind this falling direction like rising energy costs, the Russia-Ukraine conflict, and the threat to the medical services framework because of immunization obstruction by the COVID-19 variations.


With many negative advancements occurring indices have been down as of late. NDRA stock was very little irritated by the market circumstance as it proceeded with a slow ascent over the entire week. The stock flooded up on Thursday. NDRA is by all accounts partaking in the bounce back in the indices.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles